Combination therapy comprising SOS1 inhibitor and MEK inhibitor
By combining SOS1 inhibitors with MEK inhibitors, the RAS signaling pathway is synergistically inhibited, which solves the problem of poor efficacy in the treatment of SOS1-related cancers in existing technologies and achieves more effective cancer treatment results.
Patent Information
- Application Number
- CN202380032771.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-08
- Filing Date
- 2023-04-03
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies are unable to effectively inhibit the overactivation of the RAS signaling pathway, resulting in poor cancer treatment outcomes, especially for SOS1-related cancers such as glioblastoma, lung cancer, and leukemia.
Combination therapy using SOS1 inhibitors and MEK inhibitors works synergistically to enhance the efficacy of SOS1 inhibitors, increase sensitivity to cancer cells, and inhibit the RAS signaling pathway.
It significantly improved the treatment outcomes for SOS1-related cancers, prolonging overall survival, progression-free survival, and tumor regression time, enhancing disease stability, and providing improved clinical benefits.
Smart Images

Figure BDA0005072646580000051 
Figure BDA0005072646580000071 
Figure BDA0005072646580000072
Abstract
Description
Technical Field
[0001] The present invention relates to combination therapies that can be used to treat cancer. Specifically, the present invention relates to therapeutically effective combinations of Son of sevenless homolog 1 (SOS1) inhibitors and mitogen-activated protein kinase kinase (MEK) inhibitors, pharmaceutical compositions comprising the inhibitors, kits comprising the compositions, and methods of using the same. Background Art
[0002] SOS1 inhibitors
[0003] The Ras family includes v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRas), neuroblastoma RAS viral oncogene homolog (NRAS), and Harvey rat sarcoma viral oncogene (HRas), and critically regulates cell division, growth, and function in normal and altered states, including cancer (see, e.g., Simanshu et al., Cell, 2017, 170(1): 17-33; Matikas et al., Crit Rev Oncol-Hemol, 2017, 110: 1-12). RAS proteins are activated by upstream signals involving receptor tyrosine kinases (RTKs) and transduce signals to several downstream signaling pathways, such as the mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) pathway. Overactivation of RAS signaling is often observed in cancer due to mutations or alterations in RAS genes or other genes in the RAS pathway. Investigation of strategies to inhibit RAS and RAS signaling is expected to aid in the treatment of cancer and RAS-regulated disease states.
[0004] RAS proteins are guanosine triphosphatases (GTPases) that cycle between an inactive guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. RAS proteins exhibit intrinsic GTP hydrolysis and nucleotide exchange, which is further enhanced by extrinsic GTPase activating proteins (GAPs) and guanine exchange factors (GEFs). Son of sevenless homolog 1 (SOS1) is a GEF that mediates the exchange of GDP for GTP, thereby activating RAS proteins. This regulation by GAPs and GEFs is a mechanism that tightly regulates activation and inactivation under normal conditions. Mutations of several residues in all three RAS proteins are frequently observed in cancer, which cause RAS to remain primarily in an activated state (Sanchez-Vega et al., Cell, 2018, 173: 321-337; Li et al., Nature Reviews Cancer, 2018, 18: 767-777). Mutations at codons 12 and 13 disrupt GTP hydrolysis and the exchange rate of the RAS proteome. Recent biochemical analyses have demonstrated that these mutant proteins still require nucleotide cycling for activation based on their intrinsic GTPase activity and may exhibit partial sensitivity to exogenous GAPs and GEFs. Thus, mutant RAS proteins are sensitive to inhibition by upstream factors such as SOS1 GEFs (Hillig, 2019; Patricelli, 2016; Lito, 2016; Nichols, 2018).
[0005] The three major RAS-GEF families that have been identified in mammalian cells are SOS, RAS-GRF, and RAS-GRP (Rojas, 2011). RAS-GRF and RAS-GRP are expressed in central nervous system cells and hematopoietic cells, respectively, while the SOS family is widely expressed and is responsible for RTK signal transduction. The SOS family includes SOS1 and SOS2, and these proteins have approximately 70% sequence identity. SOS1 appears to be more active than SOS2 due to the rapid degradation of SOS2. Mouse SOS2 knockout is viable, while SOS1 knockout is embryonic lethal. A tamoxifen-induced SOS1 knockout mouse model was used to study the role of SOS1 and SOS2 in adult mice and demonstrated that SOS1 knockout was viable, but SOS1 / 2 double knockout was not viable (Baltanas, 2013), suggesting functional redundancy and that selective inhibition of SOS1 may have sufficient therapeutic indications to treat diseases with SOS1-RAS activation.
[0006] SOS protein is supplemented to phosphorylated RTK by interaction with growth factor receptor binding protein 2 (GRB2). Supplementation to the plasma membrane brings SOS very close to RAS and supports SOS-mediated RAS activation. SOS protein binds to RAS through a catalytic binding site that promotes nucleotide exchange and an allosteric site of the RAS family protein that binds GTP to increase the catalytic function of SOS (Freedman et al., Proc. Natl. Acad. Sci, USA, 2006, 103 (45): pp. 16692-16697). Binding to the allosteric site alleviates the spatial occlusion of the catalytic site and is therefore necessary for the full activation of the catalytic site. Due to the enhanced interaction of the key domains in the activated state, after interacting with the allosteric site, the retention of the active conformation in the catalytic site remains in an isolated state. SOS1 mutations are found in Noonan syndrome and several cancers, including lung adenocarcinoma, embryonal rhabdomyosarcoma, Sertoli cell testicular tumors, and granular cell tumors of the skin (see Denayer, E. et al., Genes-Chromosomes-Cancer, 2010, 49(3): 242-252).
[0007] GTPase activating proteins (GAPs) are proteins that stimulate the low intrinsic GTPase activity of RAS family members, thereby converting active GTP-bound RAS proteins into inactive GDP-bound RAS proteins (e.g., see Simanshu, DK, Cell, 2017, Ras Proteins and their Regulators in Human Disease). While activating alterations in the phosphatase PTPN11 (SHP2) and the GEF SOS1 occur in cancer, inactivating mutations and loss-of-function alterations in the GAP neurofibromin 1 (NF-1) also occur, resulting in uninhibited SOS1 activity and elevated activity downstream of the pathway through RAS proteins.
[0008] MEK inhibitors
[0009] The mitogen-activated protein kinase (MAPK) signaling pathway is involved in regulating various cellular activities, including but not limited to cell proliferation, survival, differentiation, and motility. The classical MAPK pathway consists of Ras (a family of related proteins expressed in all animal cell lines and organs), Raf (a family of three serine / threonine-specific protein kinases associated with retroviral oncogenes), MEK (mitogen-activated protein kinase kinase), and ERK (extracellular signal-regulated kinase), which sequentially transmit proliferation signals generated at cell surface receptors to the nucleus via cytoplasmic signaling.
[0010] MEK inhibitors target the Ras / Raf / MEK / ERK signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis.
[0011] The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer, dysregulation of the pathway is frequently observed, and it plays an important role in the carcinogenesis and maintenance of several cancers, including melanoma, pancreatic cancer, lung cancer, colorectal cancer, and breast cancer (e.g., Neuzillet et al., (2014) Pharmacology & Therapeutics 141: 160-171).
[0012] Several inhibitors that exhibit anti-MEK activity have been developed, and many of these inhibitors are being or have been studied in human clinical trials. Examples of MEK inhibitors suitable for use in the provided compositions and methods include, but are not limited to, selumetinib, 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AZD8330, 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxopyridine-3-carboxamide; PD0325901, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide; PD318088, 5-bromo-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- RIFATINIB, N-[3,4-DIFLUORO-2-(2-FLUORO-4-IODONILO)-6-METHOXYPHENYL]-1-[(2S)-2,3-DIHYDROXYPROPYL]CYCLOPRANE-1-SULFONAMIDE; BIMETINIB, 6-(4-BROBROM-2-FLUOROANILINATO)-7-FLUORO-N-(2-HYDROXYETHOXY)-3-METHYLBENZIMIDAZOLE-5-CARBOXAMIDE; RO4987655, 3,4-DIFLUORO-2-(2-FLUORO-4-IODONILO)-N-(2-HYDROXYETHOXY)-5-[(3-OXOXAZIN-2-YL)METHYL]BENZAMIDE; RO5126766 (VS-6766), 3-[[3-Fluoro-2-(Methylamino)- sulfonylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxybenzopyran-2-one; WX-554, HL-085; ClnQ-03; G-573, 7-fluoro-3-(2-fluoro-4-iodoanilino)-N-[(2S)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide; PD184161, 5-bromo-2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; RO5068760, (2S,3S)-2-[(4R)-4-[4-[(2R)-2,3-dihydroxypropoxy]phenyl]-2,5-dioxo imidazolidin-1-yl]-N-(2-fluoro-4-iodophenyl)-3-phenylbutanamide; SL327, (Z)-3-amino-3-(4-aminophenyl)sulfanyl-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile; MEK162 (Arry-162), 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; Tak-733, (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-((2-fluoro-4-iodophenyl)amino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione;GDC-0623, 5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide; U0126, (2E,3E)-2-(amino((2-aminophenyl)thio)methylene)-3-(amino((3-aminophenyl)thio)methylene)succinonitrile; trametinib, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; BI-847325, (E)-3-(3-(((4-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindolin-6-yl )-N-ethylpropiolamide; pimacitinib, (S)-N-(2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide; BIX02189, (Z)-3-(((3-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-N,N-dimethyl-2-oxoindolin-6-carboxamide; cobimetinib, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; PD-98059, 2-(2-amino-3-methoxyphenyl)-4H-benzopyran-4-one; APS-2-79, 6,7-dimethoxy-N-(2-methyl-4-phenoxyphenyl)quinazolin-4-amine; PD 198306, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-(4-iodo-2-methylbenzyl)benzamide; CI-1040, 2-(2-chloro-4-iodobenzyl)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide; SL327, (Z)-3-amino-3-((4-aminophenyl)thio)-2-(2-(trifluoromethyl)phenyl)acrylonitrile; and BIX02188, (Z)-3-(((3-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxamide. ;
[0013] The structures of these MEK inhibitors can be found, for example, in Cheng et al., Current Development Status of MEK Inhibitors, Molecules, 2017, 22,1551, and in U.S. Patents 10,370,374 and 10,323,035, and U.S. Patent Application Publication Nos. 20190144382, 20180370948, 20180296533, 20180147192, 20180118715, 20170231963, 20170183348, 20170183333, 20170166523, 20170101408, 20170096388, 20160331753, 20160 168103、20160168102、20160136150、20160108041、20150141399、20150133424、20150051209、20140378466、20140275527、20140135519、20140128442、20140080804、20130150573、20130018075、20120238599、20120208859、20120107307、20120022076、20110288092、2011026 3558、20110190257、20110183981、20110172191、20110158971、20110124622、20110112152、20110060049、20110021558、20100331334、20100267710、20100261718、20100261717、20100260714、20100256149、20100249096、20100197676、20100179124、20100063053、200902919 61. 20090264411. 20090233915. 20090215834. 20090209542. 20090156576. 20090149437. 20090143579. 20090143389. 20090131435. 20090082457. 20090030058. 20080306063. 20080280957. 20080255133. 20080177082. 20080171778. 20080166359. 20080058340. 20070299063.20070293544、20070287737、20070287709、20070244164、20070238710、20070213367、20070172843、20070112038、20070105859、20060211073、20060194802、2 0060189808, 20060189668, 20060189649, 20060154990, 20060106225, 20060089382, 20060052608, 20050256123, 20050250782 and 20050153942, the contents of which are hereby incorporated by reference in their entirety.
[0014] One MEK inhibitor suitable for the provided compositions and methods is VS-6766 having the following structure:
[0015]
[0016] 3-[[3-Fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxybenzopyran-2-one
[0017] Methods for making MEK inhibitors or pharmaceutically acceptable salts thereof or pharmaceutical compositions are well known to those skilled in the art, and MEK inhibitors are available from a wide variety of commercial suppliers in forms suitable for both research and human use. In addition, suitable MEK inhibitors for use in the compositions and methods disclosed herein and methods for preparing such inhibitors are disclosed in U.S. Patent Application Publication Nos.: 20190144382, 20180370948, 20180296533, 20180147192, 20180118715, 20170231963, 20170183348, 20170183333, 20170166523, 20170101408, 20170096388, 20160331753, 20160168103, 20160168102, 20160136 150, 20160108041, 20150141399, 20150133424, 20150051209, 20140378466, 20140275527, 20140135519, 20140128442, 20140080804, 20130150573, 20130018075, 20120238599, 20120208859, 20120107307, 20120022076, 20110288092, 20110263558, 20110190257, 201101839 81, 20110172191, 20110158971, 20110124622, 20110112152, 20110060049, 20110021558, 20100331334, 20100267710, 20100261718, 20100261717, 20100260714, 20100256149, 20100249096, 20100197676, 20100179124, 20100063053, 20090291961, 20090264411, 2009023391 5. 20090215834, 20090209542, 20090156576, 20090149437, 20090143579, 20090143389, 20090131435, 20090082457, 20090030058, 20080306063, 20080280957, 20080255133, 20080177082, 20080171778, 20080166359, 20080058340, 20070299063, 20070293544, 20070287737,20070287709, 20070244164, 20070238710, 20070213367, 20070172843, 20070112038, 20070105859, 20060211073, 20060194802, 20060189808, 20060189668, 20060189649, 20060154990, 20060106225, 20060089382, 20060052608, 20050256123, 20050250782 and 20050153942. Summary of the invention
[0018] In one aspect, the combination therapy of the invention synergistically increases the potency of the SOS1 inhibitor, resulting in improved efficacy of the SOS1 inhibitor disclosed herein. In another aspect, the combination therapy of the invention provides improved clinical benefit to patients compared to treatment with the SOS1 inhibitor disclosed herein as a single agent.
[0019] Thus, in one aspect of the invention, therapeutically effective combinations of SOS1 inhibitors are provided, such as those described in WO2021 / 127429, WO2021 / 173524, WO2022 / 026465, U.S. Provisional Patent Application 63 / 213,112 (and corresponding national and international applications and patent publications), and as described in more detail herein, for example:
[0020]
[0021] (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0022]
[0023] 3-((R)-1-((7-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0024]
[0025] (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0026]
[0027] (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0028]
[0029] (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0030]
[0031] (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0032]
[0033] 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0034]
[0035] (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0036] or a pharmaceutically acceptable salt thereof,
[0037] and MEK inhibitor compounds, such as VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040, TAK733, and other small molecule and macromolecular MEK inhibitors, or pharmaceutically acceptable salts thereof.
[0038] In another aspect of the present invention, a therapeutically effective combination is provided, comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof; and a MEK inhibitor selected from VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040, CI-1040 and TAK733, as well as other small molecule and macromolecular MEK inhibitors, or pharmaceutically acceptable salts thereof.
[0039] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound VS-6766 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0040] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound bemetinib or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0041] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound cobimetinib or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0042] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound selumetinib or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0043] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound trametinib or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0044] In another aspect of the present invention, a pharmaceutical composition for use in the method is provided, comprising: a therapeutically effective amount of a combination comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof and a MEK inhibitor compound PD-325901 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0045] In one aspect of the invention, provided herein is a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor, such as (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[ 3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl) The invention relates to a pharmaceutical composition comprising: (i) a (((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile; and a MEK inhibitor selected from VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040, TAK733, and other small molecule and macromolecular MEK inhibitors, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0046] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor VS-6766, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0047] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor bemetinib, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0048] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor cobimetinib, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0049] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor selumetinib, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0050] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor trametinib, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0051] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor PD-325901, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0052] In one embodiment, the cancer is a SOS1 -associated cancer.
[0053] In one embodiment, the SOS1-associated cancer is a brain cancer, such as a glioblastoma. In one embodiment, the SOS1-associated cancer is a lung cancer, such as a primary lung adenocarcinoma. In one embodiment, the SOS1-associated cancer is a lung cancer, such as a primary lung adenocarcinoma. In one embodiment, the SOS1-associated cancer is a leukemia, such as an acute myeloid leukemia.
[0054] In some aspects of the invention, the MEK inhibitor and the SOS1 inhibitor are the only active agents in the provided compositions and methods.
[0055] Examples of SOS1 inhibitors suitable for use in the provided compositions and methods include, but are not limited to, (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, ,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile nitrile, 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile and (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile, and pharmaceutically acceptable salts thereof.In yet another aspect, the present invention provides a method for increasing the sensitivity of cancer cells to SOS1 inhibitors or MEK inhibitors, comprising contacting cancer cells with a therapeutically effective amount of a combination comprising: a MEK inhibitor compound, such as VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040 and TAK733 and other small molecule and macromolecular MEK inhibitors, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical combination thereof. Compounds, including SOS1 inhibitors described herein such as (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)- 4-Methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl) In one embodiment, the contacting is performed in vitro. In one embodiment, the contacting is performed in vivo.
[0056] Also provided herein are methods for treating cancer in a subject in need thereof, the methods comprising: (a) determining that the cancer is associated with SOS1-mediated cancer and / or genetic alterations of the MAPK pathway (e.g., SOS1-associated cancer) (e.g., determined using an assay or kit approved by a regulatory agency (e.g., FDA-approved); and (b) administering to the patient a therapeutically effective amount of a combination comprising a SOS1 inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a MEK inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the MEK inhibitor synergistically increases the sensitivity of the SOS1-associated cancer to the SOS1 inhibitor (e.g., to (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile).
[0057] Also provided herein is a kit comprising an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof. Also provided is a kit for treating SOS1-related cancers, comprising an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a MEK inhibitor compound VS-6766 or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0058] In a related aspect, the present invention provides a kit that contains a dose of a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof, the dose being an amount effective to inhibit the proliferation of cancer cells in a subject. In some cases, the kit includes instructions with instructions for administering the SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and the MEK inhibitor compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof. The instructions can provide a user with a set of instructions for using the combination of the SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and the MEK inhibitor compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0059] In some aspects of any of the methods described herein, prior to treatment with a composition or method of the invention, the patient has been treated with one or more of chemotherapy, targeted anti-cancer agents, radiation therapy, and surgery, and optionally, the previous treatment was unsuccessful; and / or surgery has been performed on the patient, and optionally, the surgery was unsuccessful; and / or the patient has been treated with a platinum-based chemotherapeutic agent, and optionally, the patient has previously been determined to be unresponsive to treatment with a platinum-based chemotherapeutic agent; and / or the patient has been treated with a kinase inhibitor, and optionally, the previous treatment with a kinase inhibitor was unsuccessful; and / or the patient has been treated with one or more other therapeutic agents. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] Figure 1 Figure 3 Mean tumor volume (mm) of LN229 tumor-bearing mice treated with single agents (MRTX-0902, VS-6766) and combination agents. 3 ).
[0061] Figure 2 Figure 3. Mean tumor volume (mm) of NCT-H1435 tumor-bearing mice treated with single agents (MRTX-0902, VS-6766) and combination agents. 3 ). DETAILED DESCRIPTION
[0062] The present invention relates to a combination therapy for treating SOS1-related cancers. Specifically, the present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to the subject: a therapeutically effective amount of a combination comprising an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof; a pharmaceutical composition comprising a therapeutically effective amount of these inhibitors; a kit comprising these compositions and methods of using the same.
[0063] The combination of a SOS1 inhibitor or a pharmaceutically acceptable salt or a pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or a pharmaceutical composition thereof synergistically increases the efficacy of the SOS1 inhibitor against cancer cells expressing SOS1, thereby increasing the efficacy and therapeutic index of the SOS1 inhibitor or a pharmaceutically acceptable salt thereof.
[0064] definition
[0065] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. All patents, patent applications, and publications mentioned herein are incorporated by reference.
[0066] As used herein, "MEK" refers to mitogen-activated protein kinase kinase. MEK inhibitors are chemicals or drugs that inhibit mitogen-activated protein kinase kinase MEK1 and / or MEK. MEK inhibitors can be used to affect the MAPK / ERK pathway, which is often overactive in some cancers.
[0067] As used herein, "MEK" refers to compounds such as VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040 or TAK733 and other small and macromolecular MEK, or pharmaceutically acceptable salts thereof. These compounds can negatively regulate or inhibit all or part of the enzymatic activity of MEK or a mutant form of MEK.
[0068] As used herein, "MEK-related disease or disorder" refers to a disease or disorder associated with, mediated by, or having an EGFR mutation or overexpression.
[0069] As used herein, "SOS1" refers to the Sonof sevenless homolog 1 protein encoded by the SOS1 gene that is involved in signaling through the RAS pathway.
[0070] As used herein, "SOS1 inhibitor" refers to a compound that is capable of negatively regulating or inhibiting all or part of the interaction between KRAS and SOS1.
[0071] As used herein, "SOS1-associated disease or disorder" refers to a disease or disorder associated with or mediated by SOS1. A non-limiting example of a SOS1-associated disease or disorder is a SOS1-associated cancer.
[0072] As used herein, the terms "subject", "individual" or "patient", which are used interchangeably, refer to any animal, including mammals, such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, primates and humans. In some embodiments, the patient is a human. In some embodiments, the subject has experienced and / or exhibits at least one symptom of a disease or condition to be treated and / or prevented. In some embodiments, the subject has been identified or diagnosed as having a cancer with a KRas G12C mutation (e.g., using an assay or kit approved by a regulatory agency, such as FDA-approved). In some embodiments, the subject has a tumor that is positive for a KRas G12C mutation (e.g., determined using an assay or kit approved by a regulatory agency). The subject may be a subject having one or more tumors that are positive for a KRas G12C mutation (e.g., identified as positive using an assay or kit approved by a regulatory agency, such as FDA-approved). The subject may be a subject whose tumor has a KRas G12C mutation (e.g., wherein a kit or assay approved by a regulatory agency, such as FDA-approved, identifies the tumor as such). In some embodiments, the subject is suspected of having a KRas G12C gene-related cancer. In some embodiments, the subject has a clinical record indicating that the subject has a tumor with a KRas G12C mutation (and optionally, the clinical record indicates that the subject should be treated with any of the compositions provided herein).
[0073] As used herein, the term "pediatric patient" refers to a patient under the age of 16 at the time of diagnosis or treatment. The term "pediatric" can be further divided into various subgroups, including: neonates (from birth to the first month of life); infants (1 month to two years); children (two years to 12 years); and adolescents (12 to 21 years (up to but not including the twenty-second birthday)). Berhman RE, Kliegman R, Arvin AM, Nelson WE. Nelson Textbook of Pediatrics, 15th ed., Philadelphia: WB Saunders Company, 1996; Rudolph AM et al., Rudolph's Pediatrics, 21st ed., New York: McGraw-Hill, 2002; and Avery MD, First LR. Pediatric Medicine, 2nd ed., Baltimore: Williams & Wilkins; 1994.
[0074] In some embodiments of any of the methods or uses described herein, a sample (e.g., a biological sample or a biopsy sample, such as a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having an SOS1-related cancer, a patient having one or more symptoms of an SOS1-related cancer, and / or a patient at increased risk of developing an SOS1-related cancer) is used to determine whether the patient has SOS1 overexpression using an assay that may include, for example, next generation sequencing, immunohistochemistry, fluorescence microscopy, break-apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR-based amplification (e.g., RT-PCR, quantitative real-time RT-PCR, allele-specific genotyping, or ddPCR). As is well known in the art, the analysis is typically performed, for example, with at least one labeled nucleic acid probe or at least one labeled antibody or antigen-binding fragment thereof.
[0075] The term "regulatory agency" is a national agency that approves the medical use of a pharmaceutical agent in a country. For example, a non-limiting example of a regulatory agency is the US Food and Drug Administration (FDA).
[0076] As used herein, an "effective amount" of a compound is an amount sufficient to negatively regulate or inhibit the activity of a desired target (ie, SOS1 or MEK). The amount may be administered in a single dose or may be administered according to a regimen such that it is effective.
[0077] As used herein, a "therapeutically effective amount" of a compound is an amount sufficient to improve or in some way alleviate symptoms or stop or reverse the progression of a condition or negatively regulate or inhibit the activity of SOS1 or MEK. The amount can be administered in a single dose or can be administered according to a regimen, whereby it is effective.
[0078] As used herein, the "combined therapeutically effective amount" of two compounds is an amount that synergistically increases the activity of the combination (i.e., not just an additive effect) compared to the therapeutically effective amount of each compound in the combination. Alternatively, in vivo, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor compound or a pharmaceutically acceptable salt or pharmaceutical composition thereof causes a prolonged duration of overall survival ("OS") of the subject. In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof causes a prolonged duration of progression-free survival ("PFS") of the subject. In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof causes an increase in tumor regression in the subject. In one embodiment, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof causes an increase in tumor growth inhibition in a subject relative to treatment with a MEK inhibitor alone. In one embodiment, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof causes an improvement in the stable phase of the subject's disease relative to treatment with a SOS1 inhibitor alone or with a MEK inhibitor alone. The amount of each compound in the combination may be the same or different from the therapeutically effective amount of each compound when administered alone as a monotherapy, as long as the combination has a synergistic effect. The amount may be administered in a single dosage form or may be administered according to a regimen, whereby it is effective.
[0079] As used herein, "treatment" means any manner in which the symptoms or pathology of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein.
[0080] As used herein, "ameliorating" the symptoms of a particular disorder by administering a particular pharmaceutical composition refers to any relief, whether permanent or temporary, sustained or transient, attributable to or associated with administration of the composition.
[0081] As used herein, the term "about" when used to modify a numerically defined parameter (e.g., the dosage of a MEK inhibitor or SOS1 inhibitor or a pharmaceutically acceptable salt thereof, or the duration of treatment with the combination therapy described herein) means that the degree of change in the parameter may be up to 10% lower or higher than the stated value of the parameter. For example, a dosage of about 5 mg / kg can vary between 4.5 mg / kg and 5.5 mg / kg. "About" is intended to modify each parameter when used at the beginning of a parameter list. For example, about 0.5 mg, 0.75 mg, or 1.0 mg means about 0.5 mg, about 0.75 mg, or about 1.0 mg. Similarly, about 5% or more, 10% or more, 15% or more, 20% or more, and 25% or more means about 5% or more, about 10% or more, about 15% or more, about 20% or more, and about 25% or more.
[0082] As used herein, the term "contacting" refers to bringing together specified parts in an in vitro system or an in vivo system. For example, "contacting" a cancer cell includes administering a combination provided herein to an individual, such as a human, having KRas G12C, and, for example, introducing a combination provided herein into a sample containing cells or purified preparations containing KRas G12C.
[0083] MEK inhibitor compounds
[0084] In one aspect of the present invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: a SOS1 inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0085] In one embodiment, the MEK inhibitor is:
[0086]
[0087] (also known as VS-6766) or a pharmaceutically acceptable salt thereof.
[0088] In one embodiment, the MEK inhibitor is:
[0089]
[0090] (also known as bemetinib) or a pharmaceutically acceptable salt thereof.
[0091] In one embodiment, the MEK inhibitor is:
[0092]
[0093] (also known as cobimetinib) or a pharmaceutically acceptable salt thereof.
[0094] In one embodiment, the MEK inhibitor is:
[0095]
[0096] (also known as selumetinib) or a pharmaceutically acceptable salt thereof.
[0097] In one embodiment, the MEK inhibitor is:
[0098]
[0099] (also known as trametinib) or a pharmaceutically acceptable salt thereof.
[0100] In one embodiment, the MEK inhibitor is (also known as PD-325901) or a pharmaceutically acceptable salt thereof.
[0101] In one embodiment, the MEK inhibitor is CI-1040 or a pharmaceutically acceptable salt thereof.
[0102] In one embodiment, the MEK inhibitor is TAK733 or a pharmaceutically acceptable salt thereof.
[0103] The MEK inhibitors used in the methods of the present invention may have one or more chiral centers and may be synthesized as stereoisomeric mixtures, i.e., isomers of identical constitution but different arrangements of atoms in space. The compounds may be used as mixtures, or the individual components / isomers may be separated according to the manufacturer's instructions using commercially available reagents and conventional methods known to those skilled in the art for separation of stereoisomers and enantiomers, such as using (Sigma-Aldrich) or (Diacel Corp) chiral chromatography HPLC column for separation. Alternatively, the compounds of the present invention can be synthesized using optically pure chiral reagents and intermediates to prepare individual isomers or enantiomers. Unless otherwise indicated, all chiral (enantiomers and diastereoisomers) and racemic forms are within the scope of the present invention. Unless otherwise indicated, whenever the specification including the claims refers to the compounds of the present invention, the term "compound" is understood to cover all chiral (enantiomers and diastereoisomers) and racemic forms.
[0104] In one embodiment, the KRas G12C inhibitor compound adagracib used in the method includes salts of the above compounds, such as salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid and polygalacturonic acid, and salts formed by quaternary ammonium of the formula --NR+Z-, wherein R is hydrogen, alkyl or benzyl, and Z is a counter ion including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methanesulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzylate and diphenylacetate).
[0105] Methods for making the KRas G12C inhibitors disclosed herein are generally well known.
[0106] SOS1 inhibitor compounds
[0107] In one embodiment, the SOS1 inhibitor is a compound selected from the group consisting of: (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl) (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl )benzonitrile, (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-3-( (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile, or a pharmaceutically acceptable salt thereof; or a compound selected from the compounds described in ___ as described in more detail herein.
[0108] In another embodiment, the SOS1 inhibitor is a compound of the formula:
[0109]
[0110] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen, hydroxy, C1-C6 alkyl, alkoxy, -N(R 6 ) 2 、-NR 6 C(O)R 6 、-C(O)N(R 6 ) 2 、-SO 2 Alkyl, -SO 2 NR 6 alkyl, cycloalkyl, -Q-heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more R 2 substituted; each Q is independently a bond, O or NR 6 ; X is N or CR7 ; Each R 2 are independently hydroxy, halogen, cyano, hydroxyalkyl, haloalkyl, alkoxy, -N(R 6 ) 2 、-SO 2 Alkyl, -NR 6 C(O)C1-C3 alkyl, -C(O) cycloalkyl, -C(O) heterocyclyl or aryl, wherein the cycloalkyl, heterocyclyl or aryl are each optionally substituted by one or more R 11 Replacement; R 3 is hydrogen, C1-C6 alkyl, alkoxy, -N(R 10 ) 2 , cycloalkyl, haloalkyl, heterocyclyl, aryl or heteroaryl, wherein the C1-C6 alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each optionally substituted by one or more R 9 substituted; Y is a bond or heteroarylene; R 4 is aryl or heteroaryl, each optionally substituted by one or more R 5 Replace; each R 5 are independently hydroxy, halogen, cyano, hydroxyalkyl, alkoxy, C1-C3 alkyl, haloalkyl, -N(R 6 ) 2 、-LN(R 6 ) 2 or -SO 2 alkyl; L is C1-C3 alkylene; each R 6 R is independently hydrogen, C1-C3 alkyl, haloalkyl or cycloalkyl; 7 is hydrogen, cyano or alkoxy; R 8 is C1-C2 alkyl or halo-C1-C2 alkyl; each R 9 are independently hydroxy, halogen, amino, cyano, alkoxy or C1-C3 alkyl; each R 10 are independently hydrogen, C1-C3 alkyl or cycloalkyl; and each R 11 Independently C1-C3 alkyl or haloalkyl. These compounds include but are not limited to all exemplary compounds listed in WO2021 / 127429, WO2021 / 173524, WO2022 / 026465, U.S. Provisional Patent Application 63 / 213,112 (and corresponding national applications and international applications and patent publications) and as described in more detail herein, particularly including: (R) -2- methyl -3- (1- ((4- methyl -7- morpholinopyrido [3,4-d] pyridazine -1- base) amino) ethyl) benzonitrile.
[0111] In another embodiment, the SOS1 inhibitor is a compound selected from:
[0112]
[0113] (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0114]
[0115] 3-((R)-1-((7-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0116]
[0117] (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, and
[0118]
[0119] (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0120]
[0121] (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile,
[0122]
[0123] (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile,
[0124]
[0125] 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, and
[0126]
[0127] (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile and pharmaceutically acceptable salts thereof.
[0128] The SOS1 inhibitors used in the methods of the present invention may have one or more chiral centers and may be synthesized as stereoisomeric mixtures, i.e., isomers of identical constitution but different atomic arrangements in space. The compounds may be used as mixtures, or the individual components / isomers may be separated according to the manufacturer's instructions using commercially available reagents and conventional methods known to those skilled in the art for separation of stereoisomers and enantiomers, such as using (Sigma-Aldrich) or (Diacel Corp) chiral chromatography HPLC column for separation. Alternatively, the compounds of the present invention can be synthesized using optically pure chiral reagents and intermediates to prepare individual isomers or enantiomers. Unless otherwise indicated, all chiral (enantiomers and diastereoisomers) and racemic forms are within the scope of the present invention. Unless otherwise indicated, whenever the specification including the claims refers to the compounds of the present invention, the term "compound" is understood to cover all chiral (enantiomers and diastereoisomers) and racemic forms.
[0129] In one embodiment, the SOS1 inhibitor compound includes salts thereof, such as salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid and polygalacturonic acid, and salts formed with quaternary ammonium of the formula --NR+Z-, wherein R is hydrogen, alkyl or benzyl, and Z is a counterion including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methanesulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzyl acid and diphenylacetate).
[0130] Methods for making the SOS1 inhibitors disclosed herein are known. For example, co-owned applications WO2021 / 127429, WO2021 / 173524, WO2022 / 026465, U.S. Provisional Patent Application 63 / 213,112 (and corresponding national and international applications and patent publications) describe general reaction schemes for preparing compounds including adagracib, and also provide detailed synthetic routes for preparing these compounds.
[0131] Pharmaceutical composition
[0132] The SOS1 inhibitor and the MEK inhibitor or pharmaceutically acceptable salts thereof can be formulated into a pharmaceutical composition.
[0133] In another aspect, the present invention provides a pharmaceutical composition comprising an SOS1 inhibitor or a pharmaceutically acceptable salt thereof and a MEK inhibitor or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, excipient or diluent that can be used in the methods disclosed herein. The SOS1 inhibitor or a pharmaceutically acceptable salt thereof and the MEK inhibitor or a pharmaceutically acceptable salt thereof can be independently formulated by any method known in the art and can be prepared for administration by any route including but not limited to parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal or rectal. In certain embodiments, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof and / or the KRas G12C inhibitor or a pharmaceutically acceptable salt thereof are administered intravenously in a hospital setting.
[0134] In one embodiment, one or both therapeutic components may be administered by the oral route.
[0135] The carrier characteristics will depend on the route of administration. As used herein, the term "pharmaceutically acceptable" means a non-toxic material that is compatible with biological systems such as cells, cell cultures, tissues or organisms and does not interfere with the effectiveness of the biological activity of the active ingredient. Therefore, in addition to the inhibitor, the composition may also contain diluents, fillers, salts, buffers, stabilizers, solubilizers and other materials known in the art. The preparation of pharmaceutically acceptable preparations is described in, for example, Remington's Pharmaceutical Sciences 18th edition (A. Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990).
[0136] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the compound identified above and exhibits minimal or no undesirable toxicological effects. Examples of such salts include, but are not limited to, acid addition salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.) and salts formed with organic acids (such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalene disulfonic acid, and polygalacturonic acid). The compounds can also be administered in the form of pharmaceutically acceptable quaternary salts known to those skilled in the art, which specifically include quaternary ammonium salts of the formula -NR+Z-, wherein R is hydrogen, alkyl or benzyl, and Z is a counterion including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methanesulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamate, mandelate, benzoate and diphenylacetate).
[0137] The active compound is included in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver a therapeutically effective amount to the patient without causing severe toxic effects in the treated patient. In one embodiment, for all the above-mentioned conditions, the dosage range of the active compound is about 0.01 mg / kg recipient body weight / day to 300 mg / kg recipient body weight / day, such as 0.1 mg / kg recipient body weight / day to 100 mg / kg recipient body weight / day, and for example 0.5 mg / kg recipient body weight / day to about 25 mg / kg recipient body weight / day. The typical local dose range in a suitable carrier will be 0.01-3% wt / wt. The effective dose range of a pharmaceutically acceptable derivative can be calculated based on the weight of the parent compound to be delivered. If the derivative itself exhibits activity, then the effective dose can be estimated as above using the weight of the derivative or by other means known to those skilled in the art.
[0138] A pharmaceutical composition comprising a SOS1 inhibitor or a pharmaceutically acceptable salt or composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or composition thereof can be used in the methods of use described herein.
[0139] Co-administration
[0140] The SOS1 inhibitor or a pharmaceutically acceptable salt thereof and the MEK inhibitor or a pharmaceutically acceptable salt thereof can be formulated into independent or separate dosage forms that can be co-administered sequentially. Another option is that if the route of administration is the same (e.g., oral), the two active compounds can be formulated into a single form for co-administration, however, the two co-administration methods are part of the same therapeutic treatment or regimen.
[0141] The pharmaceutical compositions comprising an SOS1 inhibitor or a pharmaceutically acceptable salt thereof and / or a MEK inhibitor or a pharmaceutically acceptable salt thereof used in these methods can be used simultaneously, separately or sequentially. In one embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof is administered before the administration of the MEK inhibitor or a pharmaceutically acceptable salt thereof. In another embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof is administered after the administration of the MEK inhibitor or a pharmaceutically acceptable salt thereof. In another embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof is administered at about the same time as the administration of the MEK inhibitor compound or a pharmaceutically acceptable salt thereof.
[0142] In some cases, it will be advantageous to administer each inhibitor separately at different times and by different routes.Thus, the components of the combination, ie, the MEK inhibitor or a pharmaceutically acceptable salt thereof and the SOS1 inhibitor or a pharmaceutically acceptable salt thereof, do not necessarily need to be administered substantially simultaneously or in any order.
[0143] Tumor drugs are usually administered at a maximum tolerated dose ("MTD"), which is the highest drug dose that does not cause unacceptable side effects. In one embodiment, a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof are each administered at their corresponding MTD. In one embodiment, a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered at its MTD, and an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered at an amount less than its MTD. In one embodiment, a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered at an amount less than its MTD, and an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is administered at its MTD. In one embodiment, a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof are each administered at an amount less than their corresponding MTD. Administration can be timed so that the peak pharmacokinetic effect of one compound is consistent with the peak pharmacokinetic effect of another compound.
[0144] In one embodiment, a single dose of a MEK inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition is administered daily (i.e., at about 24 hour intervals) (i.e., QD). In another embodiment, two doses of a MEK inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition are administered daily (i.e., BID). In another embodiment, three doses of a MEK inhibitor, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition are administered daily (i.e., TID).
[0145] In one embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof or a pharmaceutical composition is administered QD. In another embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof or a pharmaceutical composition is administered BID. In another embodiment, the SOS1 inhibitor or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present invention is administered TID.
[0146] In one embodiment, a single dose of a MEK inhibitor, or a pharmaceutically acceptable salt or a pharmaceutical composition thereof, and a SOS1 inhibitor, or a pharmaceutically acceptable salt or a pharmaceutical composition thereof, are each administered once a day.
[0147] Examples of SOS1 inhibitors suitable for use in the provided compositions and methods include those mentioned herein, such as (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(4-piperazine- (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile benzonitrile, 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, and (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile.
[0148] Combination therapy
[0149] In one aspect of the invention, provided herein is a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof; and a MEK inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof. In one embodiment, the cancer is an SOS1-related cancer. In one embodiment, the SOS1-related cancer is lung cancer.
[0150] In yet another aspect, the present invention provides a method for increasing the sensitivity of cancer cells to SOS1 inhibitors, comprising contacting the cancer cells with an effective amount of a combination comprising: an SOS1 inhibitor (such as MRTX0902) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a MEK inhibitor (such as VS-6766) or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the MEK inhibitor synergistically increases the sensitivity of the cancer cells to the SOS1 inhibitor. In one embodiment, the contacting is performed in vitro. In one embodiment, the contacting is performed in vivo.
[0151] In one embodiment, the combination therapy comprises a compound having the formula:
[0152]
[0153] (MRTX0902) or a pharmaceutically acceptable salt thereof and a MEK inhibitor.
[0154] In one such embodiment, the MEK inhibitor is VS-6766.
[0155] In one such embodiment, the MEK inhibitor is bemetinib.
[0156] In one such embodiment, the MEK inhibitor is cobimetinib.
[0157] In one such embodiment, the MEK inhibitor is selumetinib.
[0158] In one such embodiment, the MEK inhibitor is trametinib.
[0159] In one such embodiment, the MEK inhibitor is PD-325901.
[0160] In one such embodiment, the MEK inhibitor is CI-1040 or TAK733.
[0161] In one embodiment, the combination therapy includes VS-6766 in combination with a SOS1 inhibitor.
[0162] In one such embodiment, the SOS1 inhibitor is:
[0163]
[0164] (R)-2-Methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile (MRTX0902).
[0165] In another such embodiment, the SOS1 inhibitor is:
[0166]
[0167] 3-((R)-1-((7-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-
[0168] d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile.
[0169] In yet another such embodiment, the SOS1 inhibitor is:
[0170]
[0171] (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]
[0172] pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile.
[0173] In yet another such embodiment, the SOS1 inhibitor is:
[0174]
[0175] (R)-2-Methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile.
[0176] In another embodiment, the SOS1 inhibitor is:
[0177]
[0178] (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile.
[0179] In another embodiment, the SOS1 inhibitor is:
[0180]
[0181] (R)-2-Methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile.
[0182] In another embodiment, the SOS1 inhibitor is:
[0183]
[0184] 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazine-1-
[0185] 1-(4-(2-methyl-1-nitropropene)carbonitrile.
[0186] In another embodiment, the SOS1 inhibitor is:
[0187]
[0188] (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile.
[0189] The methods described herein are designed to inhibit unwanted cell proliferation caused by enhanced EGFR activity within cells. The extent of the inhibitory activity of the SOS1 inhibitor-EGFR inhibitor combination in cells can be monitored, for example, by measuring cell viability and functional inhibition of RAF / MEK / ERK and PI3K / AKT effector pathway signaling (amounts of phosphorylated ERK and AKT, respectively) to assess the effectiveness of the treatment, and the dosage can be adjusted accordingly by the attending physician.
[0190] The compositions and methods provided herein can be used to treat SOS1-related cancers in subjects in need thereof, comprising administering to the subject a therapeutically effective amount of a combination comprising a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the MEK inhibitor synergistically increases the sensitivity of the SOS1-related cancer to the SOS1 inhibitor. In one embodiment, the SOS1-related cancer is a cancer in which the MAPK pathway is genetically altered. In one embodiment, the SOS1-related cancer is a cancer mediated by SOS1. In one embodiment, the SOS1-related cancer is lung cancer. In one embodiment, the SOS1-related cancer is brain cancer.
[0191] In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition causes an extension of the subject's overall survival ("OS") duration. In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition causes an extension of the subject's progression-free survival ("PFS") duration. In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition causes an increase in tumor regression in the subject. In one embodiment, relative to treatment with an SOS1 inhibitor alone, a therapeutically effective amount of a combination of an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition causes an increase in tumor growth inhibition in the subject. In one embodiment, a therapeutically effective amount of a combination comprising a SOS1 inhibitor, or a pharmaceutically acceptable salt or composition thereof, and a MEK inhibitor, or a pharmaceutically acceptable salt or composition thereof, results in improved disease stabilization in the subject compared to treatment with the SOS1 inhibitor alone.
[0192] In one embodiment, the SOS1 inhibitor is selected from (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, -((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile, or a pharmaceutically acceptable salt thereof.
[0193] In another embodiment, for SOS1 monotherapy, once disease progression has been observed, a SOS1 inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, is administered in combination with a MEK inhibitor, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the combination therapy results in an enhanced clinical benefit to the patient by prolonging OS, prolonging PFS, increasing tumor regression, increasing tumor growth inhibition, or prolonging disease stabilization in the patient.
[0194] In one embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0195] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and 3-((R)-1-((7-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0196] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0197] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0198] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0199] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0200] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0201] In another embodiment, the therapeutic combination comprises therapeutically effective amounts of VS-6766 and (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile, or a pharmaceutically acceptable salt thereof.
[0202] The compositions and methods provided herein can be used to treat a wide variety of cancers, including tumors, such as lung tumors, colorectal tumors, pancreatic tumors, prostate tumors, breast tumors, brain tumors, skin tumors, cervical cancer, testicular cancer, etc. More specifically, cancers that can be treated by the compositions and methods of the present invention include, but are not limited to, tumor types such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate, and thyroid carcinomas and sarcomas. More specifically, these compounds are useful in the treatment of: Heart: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; Lung: bronchial carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroitinoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, Insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vasodilatory peptide tumor), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); genitourinary tract: kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma) Tumor, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, mesenchymal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma); Liver: liver cancer (hepatocellular carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gallbladder cancer, ampullary carcinoma, bile duct cancer; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostosis warts), benign enchondromas, chondroblastomas, chondromyxoid fibromas, osteoid osteomas, and giant cell tumors; nervous system: skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastomas multiforme, oligodendrogliomas, schwannomas, retinoblastomas, congenital tumors), spinal neurofibromas, meningiomas, gliomas, sarcomas);Gynecology: Uterus (endometrial cancer), cervix (cervical cancer, preneoplastic cervical dysplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, supporting-lesional cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (cancer); blood: blood (myeloid leukemia ( Acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and Adrenal gland: neuroblastoma. In certain embodiments, the cancer is non-small cell lung cancer. ;
[0203] Also provided herein is a method for treating cancer in a subject in need thereof, the method comprising: (a) determining that the cancer is associated with SOS1 overexpression (e.g., using an assay or kit approved by a regulatory agency (e.g., FDA approved); and (b) administering to the patient a therapeutically effective amount of a combination comprising an SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof, wherein the MEK inhibitor synergistically increases the sensitivity of the SOS1-related cancer to the SOS1 inhibitor. In one embodiment, the MEK inhibitor is selected from VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040 and CI-1040 or TAK733 and other small and macromolecular MEK inhibitors, and the SOS1 inhibitor is selected from: (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile , 3-((R)-1-((7-((S)-hexahydropyrazine[2,1-c][1,4]oxazine-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R )-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3, 4-d]pyridazin-1-yl)amino)ethyl)benzonitrile, 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile, (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile, or a pharmaceutically acceptable salt thereof.
[0204] In one embodiment, the therapeutic combination comprises a therapeutically effective amount of (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0205] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of 3-((R)-1-((7-((S)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0206] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0207] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0208] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0209] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof.
[0210] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0211] In additional embodiments, the therapeutic combination comprises a therapeutically effective amount of (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile or a pharmaceutically acceptable salt thereof.
[0212] In one embodiment, the SOS1 inhibitor, the MEK inhibitor, or both are administered as tablets or capsules during a certain period of time. In one embodiment, the tablet or capsule formulation of the SOS1 inhibitor and / or the EGR inhibitor has one or more of the following doses: about 10 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, and about 2000 mg. In one embodiment, the SOS1 inhibitor and / or MEK inhibitor is orally administered once a day (QD) on a daily basis during a certain period of time. In one embodiment, the SOS1 inhibitor and / or MEK inhibitor is orally administered twice a day (BID) on a daily basis during a certain period of time.
[0213] In one embodiment, the SOS1 inhibitor and / or the MEK inhibitor is administered at about 20 mg to about 500 mg (e.g., about 20 mg to about 480 mg, about 20 mg to about 460 mg, about 20 mg to about 440 mg, about 20 mg to about 420 mg, about 20 mg to about 400 mg, about 20 mg to about 380 mg, about 20 mg to about 360 mg, about 20 mg to about 340 mg, about 20 mg to about 320 mg, about 20 mg to about 300 mg, about 20 mg to about 280 mg, about 20 mg to about 260 mg, about 20 mg to about 240 mg, about 20 mg to about 220 mg, about 20 mg to about 200 mg, about 20 mg to about g to about 180 mg, about 20 mg to about 160 mg, about 20 mg to about 140 mg, about 20 mg to about 120 mg, about 20 mg to about 100 mg, about 20 mg to about 80 mg, about 20 mg to about 60 mg, about 20 mg to about 40 mg, about 40 mg to about 500 mg, about 40 mg to about 480 mg, about 40 mg to about 460 mg, about 40 mg to about 440 mg, about 40 mg to about 420 mg, about 40 mg to about 400 mg, about 40 mg to about 380 mg, about 40 mg to about 360 mg, about 40 mg to about 340 mg, about 40 mg to about 320 mg, about 40 mg to about 300 mg, about 40 mg to about 2 80 mg, about 40 mg to about 260 mg, about 40 mg to about 240 mg, about 40 mg to about 220 mg, about 40 mg to about 200 mg, about 40 mg to about 180 mg, about 40 mg to about 160 mg, about 40 mg to about 140 mg, about 40 mg to about 120 mg, about 40 mg to about 100 mg, about 40 mg to about 80 mg, about 40 mg to about 60 mg, about 60 mg to about 500 mg, about 60 mg to about 480 mg, about 60 mg to about 460 mg, about 60 mg to about 440 mg, about 60 mg to about 420 mg, about 60 mg to about 400 mg, about 60 mg to about 380 mg, about 60 mg to about 360 mg g, about 60 mg to about 340 mg, about 60 mg to about 320 mg, about 60 mg to about 300 mg, about 60 mg to about 280 mg, about 60 mg to about 260 mg, about 60 mg to about 240 mg, about 60 mg to about 220 mg, about 60 mg to about 200 mg, about 60 mg to about 180 mg, about 60 mg to about 160 mg, about 60 mg to about 140 mg, about 60 mg to about 120 mg, about 60 mg to about 100 mg, about 60 mg to about 80 mg, about 80 mg to about 500 mg, about 80 mg to about 480 mg, about 80 mg to about 460 mg, about 80 mg to about 440 mg, about 80 mg to about 420 mg,about 80 mg to about 400 mg, about 80 mg to about 380 mg, about 80 mg to about 360 mg, about 80 mg to about 340 mg, about 80 mg to about 320 mg, about 80 mg to about 300 mg, about 80 mg to about 280 mg, about 80 mg to about 260 mg, about 80 mg to about 240 mg, about 80 mg to about 220 mg, about 80 mg to about 200 mg, about 80 mg to about 180 mg, about 80 mg to about 160 mg, about 80 mg to about 140 mg, about 80 mg to about 120 mg, about 80 mg to about 100 mg, about 100 mg to about 500 mg, about 100 mg to about 480 mg, about 100 mg to about 460 mg g, about 100 mg to about 440 mg, about 100 mg to about 420 mg, about 100 mg to about 400 mg, about 100 mg to about 380 mg, about 100 mg to about 360 mg, about 100 mg to about 340 mg, about 100 mg to about 320 mg, about 100 mg to about 300 mg, about 100 mg to about 280 mg, about 100 mg to about 260 mg, about 100 mg to about 240 mg, about 100 mg to about 220 mg, about 100 mg to about 200 mg, about 100 mg to about 180 mg, about 100 mg to about 160 mg, about 100 mg to about 140 mg, about 100 mg to about 120 mg, about 120 mg to about 500mg, about 120mg to about 480mg, about 120mg to about 460mg, about 120mg to about 440mg, about 120mg to about 420mg, about 120mg to about 400mg, about 120mg to about 380mg, about 120mg to about 360mg, about 120mg to about 340mg, about 120mg to about 320mg, about 120mg to about 300mg, about 120mg to about 280mg, about 120mg to about 260mg, about 120mg to about 240mg, about 120mg to about 220mg, about 120mg to about 200mg, about 120mg to about 180mg, about 120mg to about 160mg, about 120 From about 140 mg to about 140 mg, from about 140 mg to about 500 mg, from about 140 mg to about 480 mg, from about 140 mg to about 460 mg, from about 140 mg to about 440 mg, from about 140 mg to about 420 mg, from about 140 mg to about 400 mg, from about 140 mg to about 380 mg, from about 140 mg to about 360 mg, from about 140 mg to about 340 mg, from about 140 mg to about 320 mg, from about 140 mg to about 300 mg, from about 140 mg to about 280 mg, from about 140 mg to about 260 mg, from about 140 mg to about 240 mg, from about 140 mg to about 220 mg, from about 140 mg to about 200 mg, from about 140 mg to about 180 mg,about 140 mg to about 160 mg, about 160 mg to about 500 mg, about 160 mg to about 480 mg, about 160 mg to about 460 mg, about 160 mg to about 440 mg, about 160 mg to about 420 mg, about 160 mg to about 400 mg, about 160 mg to about 380 mg, about 160 mg to about 360 mg, about 160 mg to about 340 mg, about 160 mg to about 320 mg, about 160 mg to about 300 mg, about 160 mg to about 280 mg, about 160 mg to about 260 mg, about 160 mg to about 240 mg, about 160 mg to about 220 mg, about 160 mg to about 200 mg, about 160 mg to about 180 mg. 0 mg, about 180 mg to about 500 mg, about 180 mg to about 480 mg, about 180 mg to about 460 mg, about 180 mg to about 440 mg, about 180 mg to about 420 mg, about 180 mg to about 400 mg, about 180 mg to about 380 mg, about 180 mg to about 360 mg, about 180 mg to about 340 mg, about 180 mg to about 320 mg, about 180 mg to about 300 mg, about 180 mg to about 280 mg, about 180 mg to about 260 mg, about 180 mg to about 240 mg, about 180 mg to about 220 mg, about 180 mg to about 200 mg, about 200 mg to about 500 mg, about 200 mg to about about 480 mg, about 200 mg to about 460 mg, about 200 mg to about 440 mg, about 200 mg to about 420 mg, about 200 mg to about 400 mg, about 200 mg to about 380 mg, about 200 mg to about 360 mg, about 200 mg to about 340 mg, about 200 mg to about 320 mg, about 200 mg to about 300 mg, about 200 mg to about 280 mg, about 200 mg to about 260 mg, about 200 mg to about 240 mg, about 200 mg to about 220 mg, about 220 mg to about 500 mg, about 220 mg to about 480 mg, about 220 mg to about 460 mg, about 220 mg to about 440 mg, about 220 mg to about 500 mg 0mg to about 420mg, about 220mg to about 400mg, about 220mg to about 380mg, about 220mg to about 360mg, about 220mg to about 340mg, about 220mg to about 320mg, about 220mg to about 300mg, about 220mg to about 280mg, about 220mg to about 260mg, about 220mg to about 240mg, about 240mg to about 500mg, about 240mg to about 480mg, about 240mg to about 460mg, about 240mg to about 440mg, about 240mg to about 420mg, about 240mg to about 400mg, about 240mg to about 380mg, about 240mg to about 360mg,about 240 mg to about 340 mg, about 240 mg to about 320 mg, about 240 mg to about 300 mg, about 240 mg to about 280 mg, about 240 mg to about 260 mg, about 260 mg to about 500 mg, about 260 mg to about 480 mg, about 260 mg to about 460 mg, about 260 mg to about 440 mg, about 260 mg to about 420 mg, about 260 mg to about 400 mg, about 260 mg to about 380 mg, about 260 mg to about 360 mg, about 260 mg to about 340 mg, about 260 mg to about 320 mg, about 260 mg to about 300 mg, about 260 mg to about 280 mg, about 280 mg to about 500 mg. 0 mg, about 280 mg to about 480 mg, about 280 mg to about 460 mg, about 280 mg to about 440 mg, about 280 mg to about 420 mg, about 280 mg to about 400 mg, about 280 mg to about 380 mg, about 280 mg to about 360 mg, about 280 mg to about 340 mg, about 280 mg to about 320 mg, about 280 mg to about 300 mg, about 300 mg to about 500 mg, about 300 mg to about 480 mg, about 300 mg to about 460 mg, about 300 mg to about 440 mg, about 300 mg to about 420 mg, about 300 mg to about 400 mg, about 300 mg to about 380 mg, about 300 mg to about about 360 mg, about 300 mg to about 340 mg, about 300 mg to about 320 mg, about 320 mg to about 500 mg, about 320 mg to about 480 mg, about 320 mg to about 460 mg, about 320 mg to about 440 mg, about 320 mg to about 420 mg, about 320 mg to about 400 mg, about 320 mg to about 380 mg, about 320 mg to about 360 mg, about 320 mg to about 340 mg, about 340 mg to about 500 mg, about 340 mg to about 480 mg, about 340 mg to about 460 mg, about 340 mg to about 440 mg, about 340 mg to about 420 mg, about 340 mg to about 400 mg, about 34 0mg to about 380mg, about 340mg to about 360mg, about 360mg to about 500mg, about 360mg to about 480mg, about 360mg to about 460mg, about 360mg to about 440mg, about 360mg to about 420mg, about 360mg to about 400mg, about 360mg to about 380mg, about 380mg to about 500mg, about 380mg to about 480mg, about 380mg to about 460mg, about 380mg to about 440mg, about 380mg to about 420mg, about 380mg to about 400mg, about 400mg to about 500mg, about 400mg to about 480mg, about 400mg to about 460mg,In one embodiment, the amount of SOS1 inhibitor and / or MEK inhibitor is orally administered twice a day (BID) on a daily basis during a certain period of time. In one embodiment, adagracib is administered orally twice a day (BID) on a daily basis during a certain period of time.
[0214] In one embodiment, the combination therapy comprises each independently administered once or twice a day on a daily basis (during a certain period of time), for example, at about 10 mg to about 400 mg (e.g., about 10 mg to about 380 mg, about 10 mg to about 360 mg, about 10 mg to about 340 mg, about 10 mg to about 320 mg, about 10 mg to about 300 mg, about 10 mg to about 280 mg, about 10 mg to about 260 mg, about 10 mg to about 240 mg, about 10 mg to about 220 mg, about 10 mg to about 200 mg, about 10 mg to about 180 mg, about 10 mg to about 160 mg, about 10 mg to about 140 mg, about 10 mg to about 120 mg, about 10 mg to about 100 mg, about 10 mg to about 80 mg, about 10 mg to about 60 mg, about 10 mg to about 40 mg, about 10 mg to about 20 mg, about 20 mg to about 400 mg, about 20 mg to about 380 mg, about 20 mg to about 360 mg, about 20 mg to about 340 mg, about 20 mg to about 320 mg, about 20 mg to about 300 mg, about 20 mg to about 280 mg, about 20 mg to about 260 mg, about 20 mg to about 240 mg, about 20 mg to about 220 mg, about 20 mg to about 200 mg, about 20 mg to about 180 mg, about 20 mg to about 160 mg, about 20 mg to about 140 mg, about 20 mg to about about 120 mg, about 20 mg to about 100 mg, about 20 mg to about 80 mg, about 20 mg to about 60 mg, about 20 mg to about 40 mg, about 40 mg to about 400 mg, about 40 mg to about 380 mg, about 40 mg to about 360 mg, about 40 mg to about 340 mg, about 40 mg to about 320 mg, about 40 mg to about 300 mg, about 40 mg to about 280 mg, about 40 mg to about 260 mg, about 40 mg to about 240 mg, about 40 mg to about 220 mg, about 40 mg to about 200 mg, about 40 mg to about 180 mg, about 40 mg to about 160 mg, about 40 mg to about 140 mg, about 40 mg to about 120 mg, about 40 mg to about 100 mg, about 40 mg to about 80 mg, about 40 mg to about 60 mg, about 60 mg to about 400 mg, about 60 mg to about 380 mg, about 60 mg to about 360 mg, about 60 mg to about 340 mg, about 60 mg to about 320 mg, about 60 mg to about 300 mg, about 60 mg to about 280 mg, about 60 mg to about 260 mg, about 60 mg to about 240 mg, about 60 mg to about 220 mg, about 60 mg to about 200 mg, about 60 mg to about 180 mg, about 60 mg to about 160 mg, about 60 mg to about 140 mg, about 60 mg to about 120 mg, about 60 mg to about 100 mg,about 60 mg to about 80 mg, about 80 mg to about 400 mg, about 80 mg to about 380 mg, about 80 mg to about 360 mg, about 80 mg to about 340 mg, about 80 mg to about 320 mg, about 80 mg to about 300 mg, about 80 mg to about 280 mg, about 80 mg to about 260 mg, about 80 mg to about 240 mg, about 80 mg to about 220 mg, about 80 mg to about 200 mg, about 80 mg to about 180 mg, about 80 mg to about 160 mg, about 80 mg to about 140 mg, about 80 mg to about 120 mg, about 80 mg to about 100 mg, about 100 mg to about 400 mg, about 100 mg to about 380 mg , about 100 mg to about 360 mg, about 100 mg to about 340 mg, about 100 mg to about 320 mg, about 100 mg to about 300 mg, about 100 mg to about 280 mg, about 100 mg to about 260 mg, about 100 mg to about 240 mg, about 100 mg to about 220 mg, about 100 mg to about 200 mg, about 100 mg to about 180 mg, about 100 mg to about 160 mg, about 100 mg to about 140 mg, about 100 mg to about 120 mg, about 120 mg to about 400 mg, about 120 mg to about 380 mg, about 120 mg to about 360 mg, about 120 mg to about 340 mg, about 120 mg to about 3 20mg, about 120mg to about 300mg, about 120mg to about 280mg, about 120mg to about 260mg, about 120mg to about 240mg, about 120mg to about 220mg, about 120mg to about 200mg, about 120mg to about 180mg, about 120mg to about 160mg, about 120mg to about 140mg, about 140mg to about 400mg, about 140mg to about 380mg, about 140mg to about 360mg, about 140mg to about 340mg, about 140mg to about 320mg, about 140mg to about 300mg, about 140mg to about 280mg, about 140mg to about 260mg, about 140 From about 140 mg to about 240 mg, from about 140 mg to about 220 mg, from about 140 mg to about 200 mg, from about 140 mg to about 180 mg, from about 140 mg to about 160 mg, from about 160 mg to about 400 mg, from about 160 mg to about 380 mg, from about 160 mg to about 360 mg, from about 160 mg to about 360 mg, from about 160 mg to about 340 mg, from about 160 mg to about 320 mg, from about 160 mg to about 300 mg, from about 160 mg to about 280 mg, from about 160 mg to about 260 mg, from about 160 mg to about 240 mg, from about 160 mg to about 220 mg, from about 160 mg to about 200 mg, from about 160 mg to about 180 mg,From about 180 mg to about 400 mg, from about 180 mg to about 380 mg, from about 180 mg to about 360 mg, from about 180 mg to about 340 mg, from about 180 mg to about 320 mg, from about 180 mg to about 300 mg, from about 180 mg to about 280 mg, from about 180 mg to about 260 mg, from about 180 mg to about 240 mg, from about 180 mg to about 220 mg, from about 180 mg to about 200 mg, from about 200 mg to about 400 mg, from about 200 mg to about 380 mg, from about 200 mg to about 360 mg, from about 200 mg to about 340 mg, from about 200 mg to about 320 mg, from about 200 mg to about 30 0mg, about 200mg to about 280mg, about 200mg to about 260mg, about 200mg to about 240mg, about 200mg to about 220mg, about 220mg to about 400mg, about 220mg to about 380mg, about 220mg to about 360mg, about 220mg to about 340mg, about 220mg to about 320mg, about 220mg to about 300mg, about 220mg to about 280mg, about 220mg to about 260mg, about 220mg to about 240mg, about 240mg to about 400mg, about 240mg to about 380mg, about 240mg to about 360mg, about 240mg to about about 340 mg, about 240 mg to about 320 mg, about 240 mg to about 300 mg, about 240 mg to about 280 mg, about 240 mg to about 260 mg, about 260 mg to about 400 mg, about 260 mg to about 380 mg, about 260 mg to about 360 mg, about 260 mg to about 340 mg, about 260 mg to about 320 mg, about 260 mg to about 300 mg, about 260 mg to about 280 mg, about 280 mg to about 400 mg, about 280 mg to about 380 mg, about 280 mg to about 360 mg, about 280 mg to about 340 mg, about 280 mg to about 320 mg, 0mg to about 300mg, about 300mg to about 400mg, about 300mg to about 380mg, about 300mg to about 360mg, about 300mg to about 340mg, about 300mg to about 320mg, about 320mg to about 400mg, about 320mg to about 380mg, about 320mg to about 360mg, about 340mg to about 360mg, about 340mg to about 400mg, about 340mg to about 380mg, about 340mg to about 360mg, about 360mg to about 400mg, about 360mg to about 380mg, about 380mg to about 400mg, about 100mg, about 200mg,The SOS1 inhibitor and / or MEK inhibitor is orally administered in an amount of about 300 mg or about 400 mg). In one embodiment, the KRas G12C inhibitor adagracib or a pharmaceutically acceptable salt or pharmaceutical composition thereof is orally administered once a day. In another embodiment, the KRas G12C inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof is orally administered twice a day.
[0215] Those skilled in the art will recognize that both in vivo and in vitro assays using appropriate, known and generally accepted cell and / or animal models are predictive of the ability of the test compound of the combination or the combination to treat or prevent a given disorder.
[0216] Those skilled in the art will further recognize that human clinical trials, including first-in-human trials, dose-ranging and efficacy trials, can be accomplished in healthy patients and / or patients with established conditions according to methods well known in the clinical and medical arts.
[0217] Synergy
[0218] In one embodiment, the addition of a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof synergistically increases the activity of a SOS1 inhibitor compound (e.g., MRTX0902 or a pharmaceutically acceptable salt or pharmaceutical composition thereof) against a cancer or cancer cell line that overexpresses SOS1. Any method for determining whether two compounds exhibit synergy can be used to determine the synergy of the combination.
[0219] Several mathematical models have been developed to determine whether two compounds act synergistically, i.e., not just additively. For example, the Loewe additive model (Loewe (1928) Physiol. 27:47-187), the Bliss independence model (Bliss (1939) Ann. Appl. Biol. 26:585-615), the Highest Single Agent model, the ZIP model (Yadav et al., (2015) Comput Struct Biotech J 13:504-513), and other models (Chou and Talalay, (1984) Adv Enzyme Regul 22:27-55.#6382953; and Greco et al., (1995) Pharmacol Rev. Rev)》47(2):331-85.#7568331) is a well-known model in the pharmaceutical industry and can be used to calculate a "synergy score" indicating whether synergy is detected and the magnitude of the synergy. Combining these synergy scores produces a comprehensive synergy score, which can be used to evaluate and characterize MEK inhibitors (such as VS-6766) and SOS1 inhibitors (such as MRTX0902).
[0220] In general, mathematical models use data obtained from single agent values to determine the predicted additive effect of the combination compared to the observed effect of the combination. If the observed effect is greater than the predicted effect, the combination is considered synergistic. For example, the BLISS independence model converts the observed combined response (Y O ) and the predicted combined response (Y P ), the predicted combined response is obtained based on the assumption that drug-drug interactions have no effect. In general, if Y O Greater than Y P , it indicates that the combination effect is synergistic.
[0221] In some embodiments, "synergistic effect" as used herein refers to the combination of a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a SOS1 inhibitor, or a pharmaceutically acceptable salt thereof, produces an effect, e.g., any of the beneficial or desired results, including clinical results or endpoints as described herein, that is greater than the sum of the effects observed when the compound (such as one of the compounds described in the SOS1 patent applications cited herein, e.g., MRTX0902) and the MEK inhibitor, or a pharmaceutically acceptable salt thereof (e.g., VS-6766) are administered alone.
[0222] In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of 3-((R)-1-((7-((S)-hexahydropyrazin[2,1-c][1,4]oxazin-8(1H)-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-3-(1-((7-(3-(dimethylamino)-3-methylazetidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-2-methyl-3-(1-((4-methyl-7-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-3-(1-((7-(4-ethylpiperazin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-2-methyl-3-(1-((4-methyl-7-(piperazin-1-yl)pyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of 3-((R)-1-((7-((S)-3-(dimethylamino)pyrrolidin-1-yl)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-methylbenzonitrile and VS-6766. In one embodiment, the synergistic therapeutic combination comprises therapeutically effective amounts of (R)-3-(1-((6-fluoro-4-methyl-7-(4-methylpiperazin-1-yl)phthalazin-1-yl)amino)ethyl)-2-methylbenzonitrile and VS-6766.
[0223] In some embodiments, the methods provided herein can result in the use of a combination therapy for a period of between 1 day and 2 years (e.g., between 1 day and 22 months, between 1 day and 20 months, between 1 day and 18 months, between 1 day and 16 months, between 1 day and 14 months, between 1 day and 12 months, between 1 day and 10 months, between 1 day and 9 months, between 1 day and 8 months, between 1 day and 7 months, between 1 day and 6 months, between 1 day and 5 months, between 1 day and 4 months, between 1 day and 3 months, between 1 day and 2 months, between 1 day and 1 month, between one week and 2 years, between 1 week and 22 months, between 1 week and 20 months, between 1 week and 18 months). between 1 week and 16 months, between 1 week and 14 months, between 1 week and 12 months, between 1 week and 10 months, between 1 week and 9 months, between 1 week and 8 months, between 1 week and 7 months, between 1 week and 6 months, between 1 week and 5 months, between 1 week and 4 months, between 1 week and 3 months, between 1 week and 2 months, between 1 week and 1 month, between 2 weeks and 2 years, between 2 weeks and 22 months, between 2 weeks and 20 months, between 2 weeks and 18 months, between 2 weeks and 16 months, between 2 weeks and 14 months, between 2 weeks and 12 months, between 2 weeks and 10 months, between 2 weeks and 9 months, between 2 weeks and 8 months, between 2 weeks and 7 months, between 2 weeks and 6 months, between 2 weeks and 5 months, between 2 weeks and 4 months, between 2 weeks and 3 months, between 2 weeks and 2 months, between 2 weeks and 1 month, between 1 month and 2 years, between 1 month and 22 months, between 1 month and 20 months, between 1 month and 18 months, between 1 month and 16 months, between 1 month and 14 months, between 1 month and 12 months, between 1 month and 10 months, between 1 month and 9 months, between 1 month and 8 months, between 1 month and 7 months, between 1 month and 6 months, between 1 month and 6 months, between 1 month and 5 months, between 1 month and 4 months, between 1 month and 3 months, between 1 between 2 months and 2 months, between 2 months and 2 years, between 2 months and 22 months, between 2 months and 20 months, between 2 months and 18 months, between 2 months and 16 months, between 2 months and 14 months, between 2 months and 12 months, between 2 months and 10 months, between 2 months and 9 months, between 2 months and 8 months, between 2 months and 7 months, between 2 months and 6 months or between 2 months and 5 months, between 2 months and 4 months, between 3 months and 2 years, between 3 months and 22 months, between 3 months and 20 months, between 3 months and 18 months, between 3 months and 16 months, between 3 months and 14 months, between 3 months and 12 months,between 3 months and 10 months, between 3 months and 8 months, between 3 months and 6 months, between 4 months and 2 years, between 4 months and 22 months, between 4 months and 20 months, between 4 months and 18 months, between 4 months and 16 months, between 4 months and 14 months, between 4 months and 12 months, between 4 months and 10 months, between 4 months and 8 months, between 4 months and 6 months, between 6 months and 2 years, between 6 months and 22 months, between 6 months and 20 months, between 6 months and 18 months, between 6 months and 16 months, between 6 months and 14 months, between 6 months and 12 months, between 6 months and 10 months, or between 6 months 1% to 99% (e.g., 1% to 98%, 1% to 95%, 1% to 90%, 1% to 85%, 1% to 80%, 1% to 75%, 1% to 70%, 1% to 65%, 1% to 60%, 1% to 55%, 1% to 50%, 1% to 45%, 1% to 40%, 1% to 35%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 1% to 5%, 2% to 99%, 2% to 90%, 2% to 85%, 2% to 80%, 2% to 75%, 2% to 70%, 2% to 65%, 2% to 60%, 2% to 55%, 2% to 50%, 2% to 45%, 1% to 40%, 1% to 35%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 1% to 5%, 2% to 99%, 2% to 90%, 2% to 85%, 2% to 80%, 2% to 75%, 2% to 70%, 2% to 65%, 2% to 60%, 2% to 55%, 2% to 50%, 2% to 4 5%, 2% to 40%, 2% to 35%, 2% to 30%, 2% to 25%, 2% to 20%, 2% to 15%, 2% to 10%, 2% to 5%, 4% to 99%, 4% to 95%, 4% to 90%, 4% to 85%, 4% to 80%, 4% to 75%, 4% to 70%, 4% to 65%, 4% to 60%, 4% to 55%, 4% to 50%, 4% to 45%, 4% to 40%, 4% to 35%, 4% to 30%, 4% to 25%, 4% to 20%, 4% to 15%, 4% to 10%, 6% to 99%, 6% to 95%, 6% to 90%, 6% to 85%, 6% to 80%, 6% to 75%, 6% to 70%, 6% to 65%, 6% to 60%, 6% to 55%, 6% to 50%, 6% to 45%, 6% to 40%, 6% to 35%, 6% to 30%, 6% to 25%, 6% to 20%, 6% to 15%, 6% to 10%, 8% to 99%, 8% to 95%, 8% to 90%, 8% to 85%, 8% to 80%, 8% to 75%, 8% to 70%, 8% to 65%, 8% to 60%, 8% to 55%, 8% to 50%, 8% to 45%, 8% to 40%, 8% to 35%, 8% to 30%, 8% to 25%, 8% to 20%, 8% to 15%, 10% to 99%, 10% to 95%, 10% to 90%, 10% to 85%, 10% to 80%, 10% to 75%,10% to 70%, 10% to 65%, 10% to 60%, 10% to 55%, 10% to 50%, 10% to 45%, 10% to 40%, 10% to 35%, 10% to 30%, 10% to 25%, 10% to 20%, 10% to 15%, 15% to 99%, 15% to 95%, 15% to 90%, 15% to 8 5%, 15% to 80%, 15% to 75%, 15% to 70%, 15% to 65%, 15% to 60%, 15% to 55%, 15% to 50%, 15% to 55%, 15% to 50%, 15% to 45%, 15% to 40%, 15% to 35%, 15% to 30%, 15% to 25%, 15% to 20%, 20 ... % to 99%, 20% to 95%, 20% to 90%, 20% to 85%, 20% to 80%, 20% to 75%, 20% to 70%, 20% to 65%, 20% to 60%, 20% to 55%, 20% to 50%, 20% to 45%, 20% to 40%, 20% to 35%, 20% to 30%, 20% to 25% , 25% to 99%, 25% to 95%, 25% to 90%, 25% to 85%, 25% to 80%, 25% to 75%, 25% to 70%, 25% to 65%, 25% to 60%, 25% to 55%, 25% to 50%, 25% to 45%, 25% to 40%, 25% to 35%, 25% to 30%, 30% to 99%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, 30% to 55%, 30% to 50%, 30% to 45%, 30% to 40%, 30% to 35%, 35% to 99%, 35% to 95%, 35% to 99% 5% to 90%, 35% to 85%, 35% to 80%, 35% to 75%, 35% to 70%, 35% to 65%, 35% to 60%, 35% to 55%, 35% to 50%, 35% to 45%, 35% to 40%, 40% to 99%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80 %, 40% to 75%, 40% to 70%, 40% to 65%, 40% to 60%, 40% to 55%, 40% to 60%, 40% to 55%, 40% to 50%, 40% to 45%, 45% to 99%, 45% to 95%, 45% to 95%, 45% to 90%, 45% to 85%, 45% to 80%, 45% to 75%, 45% to 70%, 45% to 65%, 45% to 60%, 45% to 55%, 45% to 50%, 50% to 99%, 50% to 95%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 50% to 55%,55% to 99%, 55% to 95%, 55% to 90%, 55% to 85%, 55% to 80%, 55% to 75%, 55% to 70%, 55% to 65%, 55% to 60%, 60% to 99%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 65% to 99%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65 %, 70% to 99%, 70% to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 75% to 99%, 75% to 95%, 75% to 90%, 75% to 85%, 75% to 80%, 80% to 99%, 80% to 95%, 80% to 90%, 80% to 85%, 85% to 99%, 85% to 95%, 85% to 90%, 90% to 99%, 90% to 95%, or 95% to 100%) (e.g., compared to the size of one or more solid tumors in the patient before treatment).
[0224] The phrase "survival time" means the length of time between the identification or diagnosis of a mammal's cancer (e.g., any of the cancers described herein) by medical personnel and the mammal's death (caused by the cancer). Methods of extending the survival time of a mammal having cancer are described herein.
[0225] In some embodiments, any of the methods described herein can result in an increase in the survival time of a patient (e.g., 1% to 400%, 1% to 380%, 1% to 360%, 1% to 340%, 1% to 320%, 1% to 300%, 1% to 280%, 1% to 260%, 1% to 240%, 1% to 220%, 1% to 200%, 1% to 180%, 1% to 160%, 1% to 140%, 1% to 120%, 1% to 100%, 1% to 95%, 1% to 90%, 1% to 85%, 1% to 80%, 1% to 75%, 1% to 70%, 1% to 65%, 1% to 60%, 1% to 55%, 1% to 50%, 1% to 45%, 1% to 40%, 1% to 3 5%, 1% to 30%, 1% to 25%, 1% to 20%, 1% to 15%, 1% to 10%, 1% to 5%, 5% to 400%, 5% to 380%, 5% to 360%, 5% to 340%, 5% to 320%, 5% to 300%, 5% to 280%, 5% to 260%, 5% to 240%, 5% to 220%, 5% to 280%, 5% to 260%, 5% to 240%, 5% to 220%, 5% to 30 ...300%, 5% to 300%, 5% to 30 % to 200%, 5% to 180%, 5% to 160%, 5% to 140%, 5% to 120%, 5% to 100%, 5% to 90%, 5% to 80%, 5% to 70%, 5% to 60%, 5% to 50%, 5% to 40%, 5% to 30%, 5% to 20%, 5% to 10%, 10% to 400%, 10% to 38 0%, 10% to 360%, 10% to 340%, 10% to 320%, 10% to 300%, 10% to 280%, 10% to 260%, 10% to 240%, 10% to 220%, 10% to 200%, 10% to 180%, 10% to 160%, 10% to 140%, 10% to 120%, 10% to 1 10% to 90%, 10% to 80%, 10% to 70%, 10% to 60%, 10% to 50%, 10% to 40%, 10% to 30%, 10% to 20%, 20% to 400%, 20% to 380%, 20% to 360%, 20% to 340%, 20% to 320%, 20% to 300%, 20% to 280%, 20% to 260%, 20% to 240%, 20% to 220%, 20% to 200%, 20% to 180%, 20% to 160%, 20% to 140%, 20% to 120%, 20% to 100%, 20% to 90%, 20% to 80%, 20% to 70%, 20% to 60%, 20% to 50 %, 20% to 40%, 20% to 30%, 30% to 400%, 30% to 380%, 30% to 360%, 30% to 340%, 30% to 320%, 30% to 300%, 30% to 280%, 30% to 260%, 30% to 240%, 30% to 220%, 30% to 200%, 30% to 180%,30% to 160%, 30% to 140%, 30% to 120%, 30% to 100%, 30% to 90%, 30% to 80%, 30% to 70%, 30% to 60%, 30% to 50%, 30% to 40%, 40% to 400%, 40% to 380%, 40% to 360%, 40% to 340%, 40% to 320%, 40% to 300%, 40% to 280%, 40% to 260%, 40% to 240%, 40% to 220%, 40% to 200%, 40% to 180%, 40% to 160%, 40% to 140%, 40% to 120%, 40% to 100%, 40% to 90%, 40% to 80%, 40% to 70%, 40% to 60%, 40% to 50%, 50% to 400%, 50% to 380%, 50% to 360%, 50% to 340%, 50% to 320%, 50% to 300%, 50% to 280%, 50% to 260%, 50% to 240%, 50% to 220%, 50% to 200%, 50% to 1 80%, 50% to 160%, 50% to 140%, 50% to 140%, 50% to 120%, 50% to 100%, 50% to 90%, 50% to 80%, 50% to 70%, 50% to 60%, 60% to 400%, 60% to 380%, 60% to 360%, 60% to 340%, 60% to 320 %, 60% to 300%, 60% to 280%, 60% to 260%, 60% to 240%, 60% to 220%, 60% to 200%, 60% to 180%, 60% to 160%, 60% to 140%, 60% to 120%, 60% to 100%, 60% to 90%, 60% to 80%, 60% to 70% , 70% to 400%, 70% to 380%, 70% to 360%, 70% to 340%, 70% to 320%, 70% to 300%, 70% to 280%, 70% to 260%, 70% to 240%, 70% to 220%, 70% to 200%, 70% to 180%, 70% to 160%, 70% to 14 0%, 70% to 120%, to 100%, 70% to 90%, 70% to 80%, 80% to 400%, 80% to 380%, 80% to 360%, 80% to 340%, 80% to 320%, 80% to 300%, 80% to 280%, 80% to 260%, 80% to 240%, 80% to 220%, 80% to 200%, 80% to 180%, 80% to 160%, 80% to 140%, 80% to 120%, 80% to 100%, 80% to 90%, 90% to 400%, 90% to 380%, 90% to 360%, 90% to 340%, 90% to 320%, 90% to 300%, 90% to 280%,90% to 260%, 90% to 240%, 90% to 220%, 90% to 200%, 90% to 180%, 90% to 160%, 90% to 140%, 90% to 120%, 90% to 100%, 100% to 400%, 100% to 380%, 100% to 360%, 100% to 340%, 100% to 320%, 100% to 300%, 100% to 280%, 100% to 260%, 100% to 240%, 100% to 220%, 100% to 200%, 100% to 180%, 100% to 160%, 100% to 140%, 100% to 120%, 120% to 400%, 120% to 380% , 120% to 360%, 120% to 340%, 120% to 320%, 120% to 300%, 120% to 280%, 120% to 260%, 120% to 240%, 120% to 220%, 120% to 200%, 120% to 180%, 120% to 160%, 120% to 140%, 140% to 400%, 140% to 380%, 140% to 360%, 140% to 340%, 140% to 320%, 140% to 300%, 140% to 280%, 140% to 260%, 140% to 240%, 140% to 220%, 140% to 200%, 140% to 180%, 140% to 160% , 160% to 400%, 160% to 380%, 160% to 360%, 160% to 340%, 160% to 320%, 160% to 300%, 160% to 280%, 160% to 260%, 160% to 240%, 160% to 220%, 160% to 200%, 160% to 180%, 180% to 400%, 180% to 380%, 180% to 360%, 180% to 340%, 180% to 320%, 180% to 300%, 180% to 280%, 180% to 260%, 180% to 240%, 180% to 220%, 180% to 200%, 200% to 400%, 200% to 380% , 200% to 360%, 200% to 340%, 200% to 320%, 200% to 300%, 200% to 280%, 200% to 260%, 200% to 240%, 200% to 220%, 220% to 400%, 220% to 380%, 220% to 360%, 220% to 340%, 220% to 320%, 220% to 300%, 220% to 280%, 220% to 260%, 220% to 240%, 240% to 400%, 240% to 380%, 240% to 360%, 240% to 340%, 240% to 320%, 240% to 300%, 240% to 280%, 240% to 260%,% to 360%, 300% to 340%, 260% to 320%, 260% to 300%, 260% to 280%, 280% to 400%, 280% to 380%, 280% to 360%, 280% to 340%, 280% to 320%, 280% to 300%, 300% to 400%, 300% to 380%, 300% to 360%, 300% to 340%, or 300% to 320%) (e.g., compared to patients with similar cancers who are administered a different treatment or who receive no treatment).
[0226] In some embodiments of any of the methods described herein, prior to treatment with a composition or method of the invention, the patient has been treated with one or more of chemotherapy, targeted anti-cancer agents, radiation therapy, and surgery, and optionally, the previous treatment was unsuccessful; and / or surgery has been performed on the patient, and optionally, the surgery was unsuccessful; and / or the patient has been treated with a platinum-based chemotherapeutic agent, and optionally, the patient has previously been determined to be non-responsive to treatment with a platinum-based chemotherapeutic agent; and / or the patient has been treated with a kinase inhibitor, and optionally, the previous treatment with a kinase inhibitor was unsuccessful; and / or the patient has been treated with one or more other therapeutic agents.
[0227] Reagent test kit
[0228] The present invention also relates to a kit, which includes a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof (e.g., MRTX0902), and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof (e.g., VS-6766). A kit for treating blood cancer is also provided, which includes such a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and such a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0229] In a related aspect, the present invention provides a kit that contains a dose of a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and a dose of a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof, the dose being an amount effective to inhibit the proliferation of cancer cells (particularly cancer cells overexpressing SOS1) in a subject. In some cases, the kit includes instructions with instructions for administering the SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and the MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof. The instructions can provide a user with a set of instructions for using a combination of a SOS1 inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof and a MEK inhibitor or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0230] The following examples are intended to further illustrate certain embodiments of the present invention and are not intended to limit the scope of the present invention.
[0231] Example A
[0232] In vivo models for testing SOS1 inhibitor-MEK inhibitor combinations
[0233] Immunocompromised nude mice were inoculated with LN229 cells carrying A72S mutations in the right hind flank. When the tumor volume reached about 150 mm3, the mice were divided into four groups, 5 mice in each group. Only the vehicle was applied to the first group. The second group was administered a single-dose dose of SOS1 inhibitor MRTX0902 at a concentration of 50 mg / kg twice a day (BID), which produced the maximum biological effect but did not cause complete regression of the tumor. The third group was administered a single-dose dose of MEK inhibitor VS-6766 at a concentration of 0.3 mg / kg twice a day (BID) on Mondays, Wednesdays and Fridays (Q2D), which produced an effect less than the maximum biological effect and did not cause complete regression of the tumor. A combination of a single-dose dose of SOS1 inhibitor and a single-dose dose of MEK inhibitor was applied to the fourth group. The treatment period was 28 days. Tumor volume was measured using a caliper every two to three days, and the tumor volume was calculated by the following formula: 0.5×(length×width)2. The higher degree of tumor growth inhibition with the combination in this model suggests that combination therapy may have clinically meaningful benefit to treated subjects relative to treatment with either MEK or SOS1 inhibitors alone.
[0234] Twenty nude mice were inoculated with 5 × 10 6 LN229 cells. When the tumor volume reached about 150 mm3 (study day 0), 5 mice in each of the four groups were orally administered daily for 28 days: vehicle only (0.5% MC (4000 cps) / 0.2% Tween80 aqueous solution), 50 mg / kg BID of SOS1 inhibitor (R) -2-methyl-3- (1- ((4-methyl-7-morpholinopyrido [3, 4-d] pyridazin-1-yl) amino) ethyl) benzonitrile (MRTX0902) (0.5% MC (4000 cps) / 0.2% Tween80 aqueous solution), 0.3 mg / kg BID Q2D of MEK inhibitor VS-6766 (5% DMSO, 10% HPCD aqueous solution) or 50 mg / kg BID MRTX0902 and 0.3 mg / kg BID Q2D. The tumor volumes of five mice in each group measured on pre-specified days were averaged and are shown in Tables 1 and Figure 1 Reported in LN229 cells.
[0235] Table 1
[0236] Mean tumor volume (mm) of LN229 tumor-bearing mice treated with single agents and combination agents 3 )
[0237]
[0238] As shown in Table 1 and Figure 1 As shown in , MRTX0902 administered at 50 mg / kg twice daily as a single agent resulted in 37.6% tumor growth inhibition on day 28. VS-6766 administered at 0.3 mg / kg twice daily on Monday, Wednesday, and Friday as a single agent resulted in 92.5% tumor growth inhibition on day 28. The combination of MRTX0902 at 50 mg / kg BID and VS-6766 at 0.3 mg / kg BID Q2D resulted in -27.6% tumor regression on day 28.
[0239] These results indicate that the combination therapy elicited a higher amount of tumor growth inhibition than either single agent alone, suggesting enhanced in vivo anti-tumor efficacy of the combination against PTPN11 A72S-expressing cancers.
[0240] Example B
[0241] In vivo models for testing SOS1 inhibitor-MEK inhibitor combinations
[0242] Immunocompromised nude mice were inoculated with NCI-H1435 cells carrying the NF1 K615N mutation in the right hind flank. When the tumor volume reached about 150 mm3, the mice were divided into four groups of 5 mice in each group. The first group was administered only the vehicle. The second group was administered a single-dose dose of the SOS1 inhibitor MRTX0902 at a concentration of 50 mg / kg twice a day (BID), which produced the maximum biological effect but did not cause complete tumor regression. The third group was administered a single-dose dose of the MEK inhibitor VS-6766 at a concentration of 0.3 mg / kg twice a day (BID) on Mondays, Wednesdays and Fridays (Q2D), which produced an effect less than the maximum biological effect and did not cause complete tumor regression. A single-dose dose of the SOS1 inhibitor was administered to the fourth group in combination with a single-dose dose of the MEK inhibitor. The treatment period was 27 days. Tumor volume was measured using a caliper every two to three days, and the tumor volume was calculated by the following formula: 0.5×(length×width)2. The higher degree of tumor growth inhibition with the combination in this model suggests that combination therapy may have clinically meaningful benefit to treated subjects relative to treatment with either MEK or SOS1 inhibitors alone.
[0243] Twenty nude mice were inoculated with 5 × 10 6NCI-H1435 cells. When the tumor volume reached about 150 mm3 (study day 0), 5 mice in each of the four groups were orally administered daily for 27 days: vehicle only (0.5% MC (4000cps) / 0.2% Tween80 aqueous solution), 50mg / kg BID of the SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile (MRTX0902) (0.5% MC (4000cps) / 0.2% Tween80 aqueous solution), 0.3mg / kg BID Q2D of the MEK inhibitor VS-6766 (5% DMSO, 10% HPCD aqueous solution), or 50mg / kg BID MRTX0902 and 0.3mg / kg BID Q2D VS-6766. The tumor volumes of five mice in each group measured on pre-specified days were averaged and are shown in Tables 2 and Figure 2 Reported for NCI-H1435 cells.
[0244] Table 2
[0245] Mean tumor volume (mm) of mice bearing NCI-H1435 tumors treated with single agents and combination agents 3 )
[0246]
[0247]
[0248] As shown in Table 2 and Figure 2 As shown in , MRTX0902 administered at 50 mg / kg twice daily as a single agent resulted in 49.8% tumor growth inhibition on day 27. VS-6766 administered at 0.3 mg / kg twice daily on Monday, Wednesday, and Friday resulted in 76.4% tumor growth inhibition on day 27. The combination of MRTX0902 at 50 mg / kg twice daily and VS-6766 at 0.3 mg / kg twice daily on Monday, Wednesday, and Friday resulted in 98.1% tumor regression on day 27.
[0249] These results indicate that the combination therapy resulted in a higher amount of tumor growth inhibition than either single agent alone, suggesting enhanced in vivo anti-tumor efficacy of the combination against NF1 K615N-expressing cancers.
[0250] Although the invention has been described in conjunction with particular embodiments thereof, it will be understood that it is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention, generally following the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the basic features set forth above and as fall within the scope of the appended claims.
Claims
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a combination comprising: an SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof, and a MEK inhibitor.
2. The method according to claim 1, wherein the MEK inhibitor is selected from VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040 and CI-1040 or TAK733, or a pharmaceutically acceptable salt thereof.
3. The method according to any one of claims 1 to 2, wherein the MEK inhibitor is VS-6766.
4. The method according to any one of claims 1 to 2, wherein the MEK inhibitor is bemetinib.
5. The method according to any one of claims 1 to 2, wherein the MEK inhibitor is cobimetinib.
6. The method according to any one of claims 1 to 2, wherein the MEK inhibitor is CI-1040 or TAK733.
7. The method according to any one of claims 1 to 6, wherein the SOS1 inhibitor and the MEK inhibitor are administered on the same day.
8. The method according to any one of claims 1 to 6, wherein the SOS1 inhibitor and the MEK inhibitor are administered on different days.
9. The method according to any one of claims 1 to 8, wherein the SOS1 inhibitor is administered at a maximum tolerated dose.
10. The method of any one of claims 1 to 8, wherein the MEK inhibitor is administered at a maximum tolerated dose.
11. The method according to any one of claims 1 to 8, wherein the SOS1 inhibitor and the MEK inhibitor are each administered at a maximum tolerated dose.
12. The method of any one of claims 1 to 8, wherein the MEK inhibitor is administered in an amount below the maximum tolerated dose.
13. The method according to any one of claims 1 to 8, wherein the SOS1 inhibitor is administered in an amount below the maximum tolerated dose.
14. The method according to any one of claims 1 to 8, wherein the SOS1 inhibitor and the MEK inhibitor are each administered in an amount below the maximum tolerated dose.
15. The method of any one of claims 1 to 14, wherein the therapeutically effective amount of the combination comprising the SOS1 inhibitor and the MEK inhibitor results in a prolonged duration of overall survival, a prolonged duration of progression-free survival, an increase in tumor growth regression, an increase in tumor growth inhibition, or a prolonged period of stable disease in the subject relative to treatment with the SOS1 inhibitor alone.
16. The method of any one of claims 1 to 14, wherein the therapeutically effective amount of the combination comprising the SOS1 inhibitor and the MEK inhibitor results in a prolonged duration of overall survival, a prolonged duration of progression-free survival, an increase in tumor growth regression, an increase in tumor growth inhibition, or a prolonged period of stable disease in the subject relative to treatment with the MEK inhibitor alone.
17. A pharmaceutical composition comprising a therapeutically effective amount of a combination of a SOS1 inhibitor and a MEK inhibitor according to any one of claims 1 to 14, and a pharmaceutically acceptable excipient.
18. A method for inhibiting SOS1 activity in a cell, the method comprising contacting the cell in which inhibition of SOS1 activity is desired with an effective amount of a combination comprising: a SOS1 inhibitor (R)-2-methyl-3-(1-((4-methyl-7-morpholinopyrido[3,4-d]pyridazin-1-yl)amino)ethyl)benzonitrile or a pharmaceutically acceptable salt thereof, and a MEK inhibitor.
19. The method of claim 18, wherein the MEK inhibitor is selected from VS-6766, bemetinib, cobimetinib, selumetinib, trametinib, PD-325901, CI-1040 and TAK733, or a pharmaceutically acceptable salt thereof.
20. The method of any one of claims 18 to 19, wherein the MEK inhibitor is VS-6766.
21. The method of any one of claims 18 to 19, wherein the MEK inhibitor is bemetinib.
22. The method of any one of claims 18 to 19, wherein the MEK inhibitor is cobimetinib.
23. The method of any one of claims 18 to 19, wherein the MEK inhibitor is CI-1040 or TAK733.
24. The method of any one of claims 1 to 22, wherein the MEK inhibitor synergistically increases the sensitivity of cancer cells to the SOS1 inhibitor.
25. A method for increasing the sensitivity of cancer cells to an SOS1 inhibitor, the method comprising administering to a subject undergoing treatment an effective amount of a combination comprising: the SOS1 inhibitor or a pharmaceutically acceptable salt thereof, and a MEK inhibitor, wherein the MEK inhibitor synergistically increases the sensitivity of the cancer cells to the SOS1 inhibitor.
26. The method of any one of claims 1 to 16 and 24, wherein the therapeutically effective amount of the SOS1 inhibitor in the combination is between about 0.01 mg / kg / day to 100 mg / kg / day.
27. The method of claim 25, wherein the therapeutically effective amount of the SOS1 inhibitor in the combination is between about 0.1 mg / kg / day to 50 mg / kg / day.
28. The method of any one of claims 1 to 16 and 24, wherein the therapeutically effective amount of the MEK inhibitor in the combination is between about 0.01 mg / kg / day to 100 mg / kg / day.
29. The method of claim 27, wherein the therapeutically effective amount of the MEK inhibitor in the combination is between about 0.1 mg / kg / day to 50 mg / kg / day.
30. The method of any one of claims 1 to 16 and 24, wherein the cancer is selected from the group consisting of: Cardiac: Sarcomas (angiosarcomas, fibrosarcomas, rhabdomyosarcomas, liposarcomas), myxomas, rhabdomyomas, fibromas, lipomas, and teratomas ; Lung: bronchial carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, cartilaginous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vasodilatory peptide tumor), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); urinary Reproductive tract: Kidney (adenocarcinoma, Wilms' tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma); Liver: liver cancer (hepatocellular carcinoma), bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gallbladder cancer, ampullary cancer, bile duct cancer; Bone: Osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor; Nervous system: Skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), Meninges (meningiomas, meningosarcomas, gliosis), Brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell Tumors (pinealoma), glioblastoma multiforme, oligodendroglioma, neurothexoma, retinoblastoma, congenital tumors), spinal neurofibroma, meningioma, glioma, sarcoma); Gynecology: uterus (endometrial cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa theca cell tumor, supporting-lesional cell tumor, asexual cell tumor, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, grape-like sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma); blood : Blood (myeloid leukemias (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and Adrenal glands: neuroblastoma.
31. The method of claim 29, wherein the cancer is a SOS1-associated cancer.
32. The method of claim 29, wherein the cancer is a KRas G12C-associated cancer.
33. The method of claim 30, wherein the cancer is non-small cell lung cancer.
34. A kit comprising the pharmaceutical composition according to claim 17 for use in treating a SOS1-related cancer in a subject.
35. The kit of claim 34, further comprising an instruction sheet with instructions for administering the pharmaceutical composition.
Citation Information
Patent Citations
Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
US10323035B2
Heterocyclic compounds and uses thereof
US10370374B2
Derivatives of n-(arylamino) sulfonamides as inhibitors of mek
US20170183333A1
Compounds and compositions as inhibitors of mek
US20170183348A1
Preparation of and formulation comprising a MEK inhibitor
US20170231963A1
